

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PAR PHARMACEUTICAL, INC., and ENDO  
PAR INNOVATION COMPANY, LLC

C.A. No. 23-866-JLH-LDH

*Plaintiffs,*

v.

ZYDUS PHARMACEUTICALS (USA) INC.  
and ZYDUS LIFESCIENCES LTD.

*Defendants.*

**APPENDIX OF EXHIBITS FOR JOINT CLAIM CONSTRUCTION BRIEF**

Dated: May 31, 2024

Brian E. Farnan (Bar No. 4089)  
Michael J. Farnan (Bar No. 5165)  
FARNAN LLP  
919 North Market St., 12th Floor  
Wilmington, DE 19801  
Tel: (302) 777-0300  
Fax: (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

Martin J. Black (admitted *pro hac vice*)  
Sharon K. Gagliardi (admitted *pro hac vice*)  
Brian M. Goldberg (admitted *pro hac vice*)  
Luke M. Reilly (admitted *pro hac vice*)  
Daniel R. Roberts (admitted *pro hac vice*)  
DECHERT LLP  
Cira Centre  
2929 Arch Street  
Philadelphia, PA 19104  
Tel: (215) 994-4000  
[martin.black@dechert.com](mailto:martin.black@dechert.com)  
[sharon.gagliardi@dechert.com](mailto:sharon.gagliardi@dechert.com)  
[brian.goldberg@dechert.com](mailto:brian.goldberg@dechert.com)

Pilar G. Kraman (#5199)  
Alexis N. Stombaugh (#6702)  
Jennifer Siew (#7114)  
YOUNG CONAWAY STARGATT  
& TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
[pkraman@ycst.com](mailto:pkraman@ycst.com)  
[astombaugh@ycst.com](mailto:astombaugh@ycst.com)  
[jsiew@ycst.com](mailto:jsiew@ycst.com)

Of counsel:

Michael J. Gaertner  
James T. Peterka  
Terry Canade  
Carolyn A. Blessing  
Jacob C. Britz  
LOCKE LORD LLP  
111 South Wacker Drive  
Chicago, IL 60606

luke.reilly@dechert.com  
daniel.roberts@dechert.com

Jonathan D.J. Loeb, Ph.D. (admitted *pro hac vice*)  
DECHERT LLP  
2400 W. El Camino Real, Suite 700  
Mountain View, CA 94040-1499  
Tel: (650) 813-4995  
jonathan.loeb@dechert.com

*Attorneys for Plaintiffs Par Pharmaceutical,  
Inc. and Endo Par Innovation Company, LLC*

(312) 443-0700

Zhibin Li  
LOCKE LORD LLP  
Brookfield Place, 200 Vesey Street  
New York, New York 10281  
(212) 415-8600

*Attorneys for Defendants Zydus  
Pharmaceuticals (USA) Inc., and Zydus  
Lifesciences Limited*

**INDEX OF EXHIBITS**

<b>EXHIBIT</b>	<b>DESCRIPTION</b>	<b>JOINT APPENDIX</b>
Exhibit 1	U.S. Patent No. 11,779,587	JA1 – JA60
Exhibit 2	U.S. Patent No. 11,717,524	JA61 – JA118
Exhibit 3	Excerpts from Zydus Pharm. (USA) Inc. and Zydus Lifesciences Ltd.'s Initial Invalidity Contentions	JA119 – JA126
Exhibit 4	U.S. Patent No. 11,602,537	JA127 – JA184
Exhibit 5	March 29, 2024 Declaration of Dr. David R. Dodds and accompanying Exhibits A-F	JA185 – JA343
Exhibit 6	Declaration of Dr. Steven W. Baertschi and accompanying Exhibits 1-6	JA344 – JA514
Exhibit 7	Excerpts from the file history of U.S. Patent No. 11,779,587, July 11, 2023, Amendment and Response to Non-Final Office Action	JA515 – JA531
Exhibit 8	May 14, 2024 Rebuttal Declaration of Dr. David R. Dodds and accompanying Exhibits F-G	JA532 – JA609
Exhibit 9	May 28, 2024 Responsive Declaration of Dr. Steven W. Baertschi	JA610 – JA620
Exhibit 10	ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2) (“ICH Q3A”)	JA621 – JA636
Exhibit 11	Excerpts from the file history of U.S. Patent No. 11,779,587, Apr. 17, 2023, Non-Final Rejection	JA637 – JA653
Exhibit 12	Excerpts from the file history of U.S. Patent No. 11,717,524	JA654 – JA726